MCID: THY030
MIFTS: 52

Thyroid Gland Disease

Categories: Endocrine diseases

Aliases & Classifications for Thyroid Gland Disease

MalaCards integrated aliases for Thyroid Gland Disease:

Name: Thyroid Gland Disease 12 15
Abnormality of the Thyroid Gland 29 6
Thyroid Diseases 43 71

Classifications:



External Ids:

Disease Ontology 12 DOID:50
ICD9CM 34 246.9
MeSH 43 D013959
NCIt 49 C26893
SNOMED-CT 67 14304000
ICD10 32 E07.9
UMLS 71 C0040128

Summaries for Thyroid Gland Disease

Disease Ontology : 12 An endocrine system disease that is located in the thyroid.

MalaCards based summary : Thyroid Gland Disease, also known as abnormality of the thyroid gland, is related to autoimmune polyendocrine syndrome, type ii and vitiligo-associated multiple autoimmune disease susceptibility 1. An important gene associated with Thyroid Gland Disease is TG (Thyroglobulin), and among its related pathways/superpathways are Allograft rejection and Aldosterone synthesis and secretion. The drugs Nitroprusside and Nitric Oxide have been mentioned in the context of this disorder. Affiliated tissues include thyroid, testes and lymph node, and related phenotypes are endocrine/exocrine gland and limbs/digits/tail

Related Diseases for Thyroid Gland Disease

Diseases related to Thyroid Gland Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 777)
# Related Disease Score Top Affiliating Genes
1 autoimmune polyendocrine syndrome, type ii 33.8 TPO INS CCR6
2 vitiligo-associated multiple autoimmune disease susceptibility 1 33.2 TPO ICOSLG CCR6
3 goiter 33.1 TSHR TRH TPO THRB TG SERPINA7
4 hyperthyroidism 33.1 TSHR TRH TPO THRB TG SERPINA7
5 graves disease 1 33.0 TSHR TRH TPO THRB TG SERPINA7
6 hypothyroidism 33.0 TSHR TSHB TRH TPO THRB TG
7 cholangitis, primary sclerosing 32.8 MIR222 ICOSLG CCR6
8 hyperthyroxinemia 32.7 TSHR TRH TPO THRB TG SERPINA7
9 autoimmune disease 32.1 TSHR TPO TG INS ICOSLG CCR6
10 multinodular goiter 31.7 TSHR TPO TG RET PTH PAX8
11 subacute thyroiditis 31.7 TSHR TPO TG SERPINA7
12 myxedema 31.6 TSHR TPO TG SERPINA7
13 thyroid carcinoma 31.5 TSHR TPO TG RET CALCA
14 congenital hypothyroidism 31.5 TSHR TSHB TPO TG SERPINA7 PAX8
15 exophthalmos 31.4 TSHR TPO TG
16 differentiated thyroid carcinoma 31.4 TSHR TPO TG RET PAX8
17 thyroid carcinoma, familial medullary 31.3 TG RET CALCA
18 celiac disease 1 31.3 TPO TG PTH INS ICOSLG H2AC18
19 pernicious anemia 31.3 TPO TG CCR6
20 graves' disease 31.2 TSHR TPO THRB TG SERPINA7 PAX8
21 adenoma 31.2 TSHR TRH TG RET PTH
22 thyroiditis 31.2 TSHR TSHB TRH TPO THRB TG
23 thyroid gland medullary carcinoma 31.2 TG RET PAX8 MIR9-1 MIR222 MIR183
24 toxic diffuse goiter 31.1 TSHR TPO TG SERPINA7
25 diabetes mellitus, type i 31.1 TSHR TRH TPO TG PTH INS
26 papillary carcinoma 31.0 TSHR TPO TG RET PAX8 CALCA
27 thyroid tumor 31.0 TPO THRB TG RET
28 hashimoto thyroiditis 31.0 TSHR TSHB TPO TG RET CALCA
29 nodular goiter 31.0 TSHR TPO TG RET CALCA
30 follicular adenoma 31.0 TSHR TPO TG RET PAX8 MIR221
31 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.0 TSHR TPO TG INS
32 turner syndrome 30.9 TPO TG SERPINA7 INS
33 thyroid gland cancer 30.9 TSHR TPO THRB TG RET PTH
34 papillary thyroid microcarcinoma 30.9 TSHR TG CALCA
35 thyroid lymphoma 30.9 TPO TG CALCA
36 mechanical strabismus 30.9 TPO TG
37 hypoparathyroidism 30.9 TPO RET PTH INS CALCA
38 thyroid crisis 30.9 TSHR TPO THRB TG SERPINA7
39 parathyroid adenoma 30.9 RET PTH CALCA
40 connective tissue disease 30.8 PTH MIR9-1 MIR222 MIR221 MIR146B ICOSLG
41 nontoxic goiter 30.8 TSHR TPO TG SERPINA7 PTH ICOSLG
42 hypothyroidism, congenital, nongoitrous, 2 30.8 TSHR TPO TG SERPINA7 PAX8
43 systemic scleroderma 30.8 TPO INS ICOSLG H2AC18 CCR6
44 eye disease 30.8 TSHR MIR9-1 MIR146B INS ICOSLG H2AC18
45 thyroid cancer, nonmedullary, 2 30.8 TSHR THRB TG PAX8 CALCA
46 hypothyroidism, congenital, nongoitrous, 1 30.8 TSHR TG PTH
47 postsurgical hypothyroidism 30.7 TRH TPO TG RET PTH
48 plummer's disease 30.7 TSHR TPO THRB TG PTH
49 primary hyperparathyroidism 30.7 RET PTH INS CALCA
50 neonatal thyrotoxicosis 30.7 TSHR TG

Comorbidity relations with Thyroid Gland Disease via Phenotypic Disease Network (PDN):


Hypertension, Essential Hypothyroidism

Graphical network of the top 20 diseases related to Thyroid Gland Disease:



Diseases related to Thyroid Gland Disease

Symptoms & Phenotypes for Thyroid Gland Disease

MGI Mouse Phenotypes related to Thyroid Gland Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.61 INS PAX8 PTH RET TG THRB
2 limbs/digits/tail MP:0005371 9.17 PAX8 PTH RET TG THRB TPO

Drugs & Therapeutics for Thyroid Gland Disease

Drugs for Thyroid Gland Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 375)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitroprusside Approved, Investigational Phase 4 15078-28-1 11963622
2
Nitric Oxide Approved Phase 4 10102-43-9 145068
3
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
4
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
5
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
6
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
7 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
8
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
9
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
10
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
11
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
12
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
13
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
14
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
15
Acetaminophen Approved Phase 4 103-90-2 1983
16
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
17
Codeine Approved, Illicit Phase 4 76-57-3 5284371
18
Metformin Approved Phase 4 657-24-9 14219 4091
19
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
20
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
21 Antineoplastic Agents, Hormonal Phase 4
22 Antiemetics Phase 4
23 Vasodilator Agents Phase 4
24 Methylprednisolone Acetate Phase 4
25 Neuroprotective Agents Phase 4
26 Hypnotics and Sedatives Phase 4
27 Psychotropic Drugs Phase 4
28 Lipid Regulating Agents Phase 4
29 Hypolipidemic Agents Phase 4
30 Antimetabolites Phase 4
31 glucocorticoids Phase 4
32 triamcinolone acetonide Phase 4
33 Triamcinolone diacetate Phase 4
34 Triamcinolone hexacetonide Phase 4
35 Technetium Tc 99m Medronate Phase 4
36 Dopamine Agents Phase 4
37 Carboxymethylcellulose Sodium Phase 4
38 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
39 Anticholesteremic Agents Phase 4
40 Dopamine Antagonists Phase 4
41 Antipsychotic Agents Phase 4
42 Red Yeast Phase 4
43 Red yeast rice Phase 4
44 Platelet Aggregation Inhibitors Phase 4
45 policosanol Phase 4
46 Protective Agents Phase 4
47 Proxymetacaine Phase 4
48 Viscosupplements Phase 4
49 Adjuvants, Immunologic Phase 4
50 Narcotics Phase 4

Interventional clinical trials:

(show top 50) (show all 685)
# Name Status NCT ID Phase Drugs
1 Does Sodium Nitroprusside Infusion Affect Thyroidal Function in Patients Undergoing Coronary Artery Bypass Grafting, a Prospective Randomized Clinical Trial. Unknown status NCT00636584 Phase 4 sodium nitroprusside;placebo
2 Total Thyroidectomy With Harmonic Scalpel® Versus Standard Surgery. Open Multicentric Randomized Controlled Trial Unknown status NCT00385983 Phase 4
3 Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Mono-Therapy, With Concurrent Radioactive Iodine , or Combination With Surgery in Subjects With Advanced Malignant Thyroid Tumors Unknown status NCT00902122 Phase 4 rAd-p53 gene;p53 gene therapy
4 Effects of Dexmedetomidine on Cough Response and Postoperative Recovery Quality in Patients Undergoing Thyroid Surgery With General anesthesia---a Randomized Control Double-Blind Clinical Trial Unknown status NCT02613806 Phase 4 Dexmeditomidine;normal saline
5 Efficacy of Dexmedetomidine for Cough Suppression During Anesthetic Emergence in Patients Undergoing Thyroid Surgery: A Randomized, Double Blinded, Controlled Trial Unknown status NCT03312413 Phase 4 Dexmedetomidine Hydrochloride;Normal Saline;Dexmedetomidine Hydrochloride;Dexmedetomidine Hydrochloride
6 The Use of Lu177 in the Treatment of Progressive and Unresectable Metastatic Medullary Thyroid Cancer Unknown status NCT01915485 Phase 4
7 Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease Unknown status NCT02339142 Phase 4 intravenous corticosteroids (methylprednisolone)
8 A Double-masked, Methylprednisolone-control, Efficacy and Safety Study of 99Tc-MDP for Thyroid Associated Ophthalmopathy. Completed NCT03948191 Phase 4 Methylprednisolone;99Tc-MDP(99Technetium-Methylenediphosphonate Injection)
9 Is the Routine Pressure Dressing After Thyroidectomy Necessary? A Prospective Randomized Controlled Study Completed NCT00400465 Phase 4
10 Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment Completed NCT03969108 Phase 4 Indocyanine Green
11 Is it Possible to Increase Quality of Life, Using Recombinant TSH Instead of Withdrawal of Thyroid Hormone Treatment, Before Iodine Uptake in Patients With Thyroid Cancer? Completed NCT00604318 Phase 4 rhTSH
12 Multicentric Randomized Controlled Study of Percutaneous Laser Ablation Versus Follow Up in Benign Thyroid Nodules. Long Term Results Completed NCT00858104 Phase 4
13 Effect of Thyroid Hormone Replacement on Fatigability in Untreated Older Adults With Subclinical Hypothyroidism Completed NCT02500342 Phase 4 Levothyroxine;Placebo
14 Novel Biomarkers and Skeletal Outcomes Associated With Subclinical Thyroid Dysfunction: a Prospective Evaluation and Impact of Treatment Completed NCT02491008 Phase 4 Levothyroxine;Placebo
15 A Dosimetry Study of Radioiodine (131-I) Uptake Following the Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal Completed NCT00001730 Phase 4 Thyrogen
16 Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections Completed NCT01599273 Phase 4 subconjunctival triamcinolone injection
17 Impact of Thyroid Hormone Replacement on Cardiac Function: a Randomized Placebo-Controlled Trial in Older Adults With Subclinical Hypothyroidism Completed NCT02832960 Phase 4 Levothyroxine;Placebo
18 Impact of Thyroid Hormone Replacement on Progression of Atherosclerosis : a Randomized Placebo-Controlled Trial in Older Adults With Subclinical Hypothyroidism. Completed NCT02832934 Phase 4 Levothyroxine;Placebo
19 Risperidone Augmentation for Treatment-Resistant Aggression in ADHD Completed NCT00297739 Phase 4 Risperidone
20 Long Term Efficacy and Tolerability of a Nutraceutical Combination (Red Yeast Rice, Policosanols and Berberine) in Low-moderate Risk Hypercholesterolemic Patients: a Double-blind, Placebo Controlled Study Completed NCT02078167 Phase 4
21 Prospective Single Arm Post Marketing Phase IV Study to Assess the Safety and Efficacy of Lenvatinib in Subjects With Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid Cancer Recruiting NCT03573960 Phase 4 Lenvatinib
22 A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
23 Phase IV Study of Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease Recruiting NCT01738243 Phase 4 Hyaluronic Acid Gel injection;Saline injection
24 Effects of Long-term L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Patients With Hypothyroidism Active, not recruiting NCT01848171 Phase 4 L-thyroxine
25 The Beneficial Effect of L-Thyroxine Long -Term Replacement on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism: A Prospective Study Active, not recruiting NCT01831869 Phase 4 L-thyroxine
26 Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery Active, not recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
27 An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease Active, not recruiting NCT01496313 Phase 4 300mg vandetanib;150mg vandetanib
28 Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules Size in Type 2 Diabetes: a 2-years Prospective Multicentric Study Not yet recruiting NCT04298684 Phase 4 METFORMIN;Sitagliptin
29 Levothyroxine Replacement With Liquid Gel Capsules or Tablets in Post-thyroidectomy Stage in Low Risk Differentiated Thyroid Cancer Patients Terminated NCT02946918 Phase 4 Levothyroxine
30 The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. Withdrawn NCT01927406 Phase 4 Prostaglandin Analog;Timolol
31 Medico-economic Evaluation Comparing the Use of Ultrasonic Scissors to the Conventional Techniques of Haemostasis in Thyroid Surgery by Cervicotomy Unknown status NCT01551914 Phase 3
32 Ultrasound Guided Interstitial Laser Photocoagulation on Benign Thyroid Nodules Unknown status NCT00150150 Phase 3
33 Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients - Estimabl Unknown status NCT00435851 Phase 3 Thyrogen, thyroid hormone withdrawal, iode 131
34 "ShearWave" Elastography Interest in the Management of Thyroid Nodules Completed NCT01335828 Phase 2, Phase 3
35 Efficacy of Subfascial Approach in Thyroidectomy to Quality of Life in Thyroid Disease Patients: Prospective Randomized Study Completed NCT01616316 Phase 2, Phase 3
36 A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Medullary Thyroid Carcinoma(ALTER01031) Completed NCT02586350 Phase 2, Phase 3 Anlotinib;Placebo
37 Preoperative Single-dose Steroid Application for the Treatment of Nausea and Vomiting After Thyroid Surgery Completed NCT01189292 Phase 3 Dexamethasone
38 Prospective, Randomized, Double Blind, Multicenter Study for Hyalobarrier ® to Evaluate Anti-adhesive Effect and Safety Compared to Guardix-SG® After Thyroidectomy Completed NCT01696305 Phase 3
39 Phase 3 Study of Treatment of Soft Tissue Expansion and Exophthalmos in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues. Completed NCT02155049 Phase 3 bimatoprost 0.03%
40 Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma: A Prospective Randomized Controlled Trial Completed NCT00795782 Phase 3
41 A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer Completed NCT00984282 Phase 3 Sorafenib (Nexavar, BAY43-9006);Placebo
42 The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy Completed NCT01579539 Phase 3 Methylprednisolone;Esomeprazole
43 Impact and Cost Efficiency of Bilateral, Superficial Cervical Block in Thyroid Surgery Under General Anesthesia Completed NCT00472446 Phase 2, Phase 3 bilateral superficial cervical block;placebo bilateral superficial cervical block
44 Value of Sentinel Lymph Node Biopsy to Lateral Neck Lymph Node in Thyroid Carcinoma: Prospective Study Completed NCT01137097 Phase 2, Phase 3
45 Clinical Trial Phase III, Parallel Group, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab Administration in Patients With Moderate-to-severe or Sight-threatening Graves' Ophthalmopathy (GO), That Had Not Responded Adequately to Treatment With Intravenous Corticoid Pulses. Completed NCT01297699 Phase 3 Tocilizumab (RoActemra®);Sterile 0.9% Sodium Chloride
46 Thyroid Nodules Treated With Percutaneous Radiofrequency Thermal Ablation: a Comparative Study Completed NCT01649206 Phase 3
47 Follow-up of Thyroid Cancer Patients From Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method. Completed NCT00295763 Phase 3 Thyrogen (thyrotropin alfa for injection)
48 The Role of Sentinel Lymph Node Biopsy (SLNB) In the Management of Differentiated Thyroid Cancer Completed NCT00794053 Phase 3
49 A Randomized, Controlled, Open-Label, Multi-National Pilot Study of Thyroid Remnant Ablation Comparing the Safety and Ablation Rate Following 131I Administration Using Thyrogen® Versus the Safety and Ablation Rate Following 131I Administration in the Hypothyroid State Completed NCT00196729 Phase 3 Thyrogen + Radioiodine (131I)
50 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer Completed NCT01321554 Phase 3 Lenvatinib;Placebo;Lenvatinib

Search NIH Clinical Center for Thyroid Gland Disease

Cochrane evidence based reviews: thyroid diseases

Genetic Tests for Thyroid Gland Disease

Genetic tests related to Thyroid Gland Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Thyroid Gland 29

Anatomical Context for Thyroid Gland Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Thyroid Gland Disease:

19
Thyroid

MalaCards organs/tissues related to Thyroid Gland Disease:

40
Thyroid, Testes, Lymph Node, Eye, Breast, T Cells, Bone

Publications for Thyroid Gland Disease

Articles related to Thyroid Gland Disease:

(show top 50) (show all 4766)
# Title Authors PMID Year
1
ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of hyperthyroidism and hypothyroidism. 61
32438340 2020
2
The interplay between thyroid and liver: implications for clinical practice. 61
32166702 2020
3
Familial Aggregation and Heritability of Nonmedullary Thyroid Cancer in an Asian Population: A Nationwide Cohort Study. 61
32333767 2020
4
Genetic Study in a Large Cohort Supported Different Pathogenesis of Graves' Disease and Hashimoto's Hypothyroidism. 61
32246145 2020
5
Association between thyroid gland diseases and breast cancer: a case-control study. 61
32424720 2020
6
Long-term outcomes of graves disease in children treated with anti-thyroid drugs. 61
31980413 2020
7
Thyroid disease in the time of COVID-19. 61
32507963 2020
8
The Detection of Serum IgMs to Thyroglobulin in Subacute Thyroiditis Suggests a Protective Role of IgMs in Thyroid Autoimmunity. 61
31996918 2020
9
Comparative study of bilateral axillo-breast approach endoscopic and robotic thyroidectomy: propensity score matching analysis of large multi-institutional data. 61
32528910 2020
10
The Impact of Thyroid Diseases on the Working Life of Patients: A Systematic Review. 61
32560169 2020
11
Reply to Swaen's Letter regarding 'Environmental exposure to pesticides and risk of thyroid diseases'. 61
32497563 2020
12
Letter to the Editor in response to Requena et al: Environmental exposure to pesticides and risk of thyroid diseases (Requena et al., 2019). 61
32526249 2020
13
Interference on Iodine Uptake and Human Thyroid Function by Perchlorate-Contaminated Water and Food. 61
32512711 2020
14
The Genetic Basis of Thyroid Function: Novel Findings and New Approaches. 61
32271924 2020
15
The epidemiology of comorbidities among multiple sclerosis patients in northeastern Poland. 61
32197130 2020
16
Clinical diagnostic performance of a fully automated TSI immunoassay vs. that of an automated anti‑TSHR immunoassay for Graves' disease: a Chinese multicenter study. 61
32562184 2020
17
Thyroid-Gut-Axis: How Does the Microbiota Influence Thyroid Function? 61
32545596 2020
18
Diagnostic relevance of 18F-FDG PET/CT in newly diagnosed patients with monoclonal gammopathy of undetermined significance (MGUS): Single-center experience. 61
32567936 2020
19
Association of cytokine Th2 gene polymorphisms with autoimmune thyroid diseases in Tunisian population. 61
31900992 2020
20
Associations of Yersinia enterocolitica infection with autoimmune thyroid diseases: a systematic review and meta-analysis. 61
32564766 2020
21
Gut dysbiosis is associated with primary hypothyroidism with interaction on gut-thyroid axis. 61
32519746 2020
22
Autoimmune Thyroid Disease is Associated with a Lower Prevalence of Diabetic Retinopathy in Patients with Type 1 Diabetic Mellitus. 61
32466561 2020
23
Incidence of thyroid disorders in the second decade of adequate iodine supply in Slovenia. 61
32377868 2020
24
Autoimmune Thyroid Diseases after 25 years of Universal Salt Iodization: An Epidemiologic Study of Chinese Adults in Areas with Different Water Iodine Levels. 61
32436480 2020
25
Impact of Computed Tomography Scans on the Risk of Thyroid Disease in Minor Head Injury Patients: A Population-Based Retrospective Cohort Study. 61
32486020 2020
26
Nutraceuticals in Thyroidology: A Review of in Vitro, and in Vivo Animal Studies. 61
32397091 2020
27
Evaluation of circulating cell free DNA in plasma as a biomarker of different thyroid diseases. 61
30826312 2020
28
Reference intervals for thyroid-stimulating hormone and thyroid hormones using the access TSH 3rd IS method in China. 61
31912542 2020
29
Thyroid cancer risk factors and Pakistani University students' awareness towards its preventive practice. 61
32437225 2020
30
The use of prohibited substances for therapeutic reasons in athletes affected by endocrine diseases and disorders: the therapeutic use exemption (TUE) in clinical endocrinology. 61
31734891 2020
31
Spot urine iodine levels below the WHO recommendation are not related to impaired thyroid function in healthy children and adolescents. 61
32390124 2020
32
Mechanisms of action of metformin in type 2 diabetes: Effects on mitochondria and leukocyte-endothelium interactions. 61
32535544 2020
33
Post-thyroidectomy tracheocutaneous fistula; A case report with literature review. 61
32540679 2020
34
Biomarkers of exposure and early effect in three contaminated sites of southern Italy: protocols for etiological epidemiological studies. 61
32393613 2020
35
Predictive risk factors for autoimmune thyroid diseases in patients with pernicious anemia. 61
31780218 2020
36
Decreased Immunoglobulin G Core Fucosylation, A Player in Antibody-dependent Cell-mediated Cytotoxicity, is Associated with Autoimmune Thyroid Diseases. 61
32024769 2020
37
Immunomodulatory Effects of Vitamin D in Thyroid Diseases. 61
32429416 2020
38
A Novel Mouse Model of Autoimmune Thyroiditis Induced by Immunization with Adenovirus Containing Full-Length Thyroglobulin cDNA: Implications to Genetic Studies of Thyroid Autoimmunity. 61
32228171 2020
39
Gene polymorphisms of VEGF and VEGFR2 are associated with the severity of Hashimoto's disease and the intractability of Graves' disease, respectively. 61
32074519 2020
40
Does severe vitamin D deficiency impact obstetric outcomes in pregnant women with thyroid autoimmunity? 61
30173587 2020
41
Autoimmune and non-autoimmune thyroid dysfunction in HCV infected and HCV-HIV co-infected patients before and after interferon alpha therapy: A prospective study. 61
31266712 2020
42
THE CORRELATION BETWEEN METABOLIC DISORDERS AND TPOAB/TGAB: A CROSS-SECTIONAL POPULATION-BASED STUDY. 61
32339031 2020
43
Poorly differentiated thyroid carcinoma with pleomorphic giant cells-a case report. 61
32239274 2020
44
[Assessment of self-reported cardiovascular and metabolic diseases in the German National Cohort (GNC, NAKO Gesundheitsstudie): methods and initial results]. 61
32157352 2020
45
High prevalence of autoimmune diseases in women with endometriosis: a case-control study. 61
31476950 2020
46
Pediatric thyroid ultrasound: a radiologist's checklist. 61
32166365 2020
47
The Role of Vitamin D Receptor Gene Polymorphisms in Thyroid-Associated Orbitopathy. 61
31424978 2020
48
Prevalence and risk of thyroid diseases in myasthenia gravis. 61
32329050 2020
49
[Hereditary predispositions to follicular thyroid tumors]. 61
32192806 2020
50
General properties of autoimmune thyroid diseases and associated morbidities. 61
32126013 2020

Variations for Thyroid Gland Disease

ClinVar genetic disease variations for Thyroid Gland Disease:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 COL7A1 NM_000094.3(COL7A1):c.1442G>A (p.Arg481His)SNV Likely pathogenic 373954 rs147040026 3:48629171-48629171 3:48591738-48591738

Expression for Thyroid Gland Disease

Search GEO for disease gene expression data for Thyroid Gland Disease.

Pathways for Thyroid Gland Disease

GO Terms for Thyroid Gland Disease

Cellular components related to Thyroid Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.36 TSHB TPO TG SERPINA7 PTH MIR222

Biological processes related to Thyroid Gland Disease according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.07 TSHR TSHB TRH PTH INS CCR6
2 gene silencing by miRNA GO:0035195 9.98 MIR9-1 MIR222 MIR221 MIR183 MIR146B
3 positive regulation of protein kinase B signaling GO:0051897 9.81 RET MIR222 MIR221 INS
4 miRNA mediated inhibition of translation GO:0035278 9.77 MIR9-1 MIR222 MIR221
5 positive regulation of epithelial cell migration GO:0010634 9.63 MIR222 MIR221 CCR6
6 hormone biosynthetic process GO:0042446 9.58 TPO TG
7 negative regulation of cell adhesion molecule production GO:0060354 9.57 MIR222 MIR221
8 positive regulation of axon regeneration GO:0048680 9.56 MIR222 MIR221
9 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.55 MIR222 MIR221
10 negative regulation by host of viral genome replication GO:0044828 9.54 MIR222 MIR221
11 negative regulation of interleukin-21 biosynthetic process GO:0045391 9.49 MIR222 MIR221
12 negative regulation of interleukin-21 production GO:0032705 9.48 MIR222 MIR221
13 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.43 MIR222 MIR221
14 positive regulation of Schwann cell migration GO:1900149 9.4 MIR222 MIR221
15 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.37 MIR222 MIR221
16 thyroid gland development GO:0030878 9.33 THRB TG PAX8
17 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.32 MIR222 MIR221
18 thyroid-stimulating hormone signaling pathway GO:0038194 9.26 TSHR PAX8
19 hormone-mediated signaling pathway GO:0009755 9.26 TSHR TSHB TRH THRB
20 cell-cell signaling GO:0007267 9.1 TSHR TSHB TRH PTH INS CALCA

Molecular functions related to Thyroid Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor activity GO:0038023 9.56 TSHR THRB RET CCR6
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.55 MIR9-1 MIR222 MIR221 MIR183 MIR146B
3 hormone activity GO:0005179 9.1 TSHB TRH TG PTH INS CALCA
4 thyroid-stimulating hormone receptor activity GO:0004996 8.96 TSHR PAX8

Sources for Thyroid Gland Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....